← Insiders

MIR

Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.

Research, not advice.

À propos

Mirion Technologies, Inc.

Nom
Mirion Technologies, Inc.
Secteur
Industrials
Industrie
Industrial - Machinery
Bourse
NYSE
Capitalisation
$3.6B
Employés
3,281
PDG
Thomas D. Logan
Site web
https://www.mirion.com
Marché
GTESGXOJBTMMIDDMOG-ANPO

Mirion Technologies, Inc., established in 2005 and formerly known as Global Monitoring Systems, Inc. until its name change in January 2006, is based in Atlanta, Georgia. The company specializes in providing a comprehensive suite of specialized solutions for radiation detection, measurement, analysis, and monitoring. Its operations span a wide international footprint, covering countries such as the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, the Netherlands, Estonia, and Japan. The business is organized into two distinct operating segments: Medical and Industrial. The Medical segment delivers critical solutions aimed at enhancing patient safety and treatment accuracy within healthcare environments. Offerings here include quality assurance and dosimetry tools for radiation oncology, specialized patient safety systems for diagnostic imaging and radiation therapy centers, and precision calibration and verification solutions for medical imaging and treatment accuracy. Furthermore, it supplies radionuclide therapy products, which encompass shielding, handling equipment, dedicated medical imaging furniture, and rehabilitation aids for nuclear medicine applications. This segment fundamentally supports advancements in medical diagnostics, cancer treatment, professional safety for practitioners, and patient recovery. Conversely, the Industrial segment addresses vital requirements in radiation safety, measurement, and analysis across non-medical industries. It furnishes clients with personal radiation detection devices, identification equipment, and advanced analytical instrumentation. Mirion's extensive product and solution portfolio includes a variety of items such as nuclear medicine preparations, personal dosimeters, contamination and clearance monitoring systems, and sophisticated reactor instrumentation and control equipment. They also provide both medical and industrial imaging systems along with their related accessories, in addition to specialized instruments for alpha spectroscopy, alpha/beta counting, and gamma spectroscopy detector systems. Supplementary offerings include electrical penetration components, cancer diagnostic tools, software solutions, and a range of other services. Mirion serves a broad and varied clientele across numerous sectors. This includes healthcare providers like hospitals, clinics, urgent care facilities, dental and veterinary offices, and specialized radiation treatment centers, as well as original equipment manufacturers (OEMs) for radiation therapy. Beyond healthcare, their customers extend to research laboratories, military organizations, governmental agencies, various industrial enterprises, power and utility companies, reactor design firms, and nuclear power plants (NPPs).

Price (1 year)

Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.

ACHAT TOTAL: 20000 titres (~312000 USD)

Insiders
Schopfer Brian
Total bought
$312,000

Avg buy (VWAP, 90d window) $15.60 vs last close $14.81 (-5.1%)

Total sold
—

Avg sell (VWAP, 90d window) —

Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.

Last activity
2026-09-02
Liquidity
Liquid $61,092,213/day · 20d vol
Last synced
2026-10-23 21:10:44 Synced via automated research pipeline

Sign in to request a sync of this company's price history and timing levels.

Insider holdings as a share of total assets aren't available for this company.

Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.

Recent Form 4

Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.

Date Person Side Shares Price Value Form 4
2026-09-02 Schopfer Brian Buy · P 20,000 $15.60 $312,000 Form 4

Congressional trades

STOCK Act disclosures (90-day window)

Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.

No STOCK Act disclosures for this company in this window.

Signal

Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.

MIR presents a compelling turnaround story in 2025 with positive net profitability and improving margins, supported by strong liquidity (85) and solid fundamentals trend (75).

The first sentence of the analysis written for MIR on 2026-10-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.

Neutral signal Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.

Factor checklist — research, not advice

A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.

  • Insider Supports a bullish reading. Open-market purchases outweigh sales
  • Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
  • Congress Unavailable or mixed. No purchase disclosures in the stored window
  • Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
  • Financial indicators Supports a bullish reading. Current ratio 2.83 · operating margin 5.6%

Suggested stop 13.84, nearest stored support minus 0.5 ATR(6.5% under the last close). Reward/risk to the next stored resistance is 0.57. Wait — that reward/risk is under 2. Research, not advice. Not an order.

Recent news

Market snapshot

Financial ratios

MetricTrend2025-12-312024-12-312023-12-312022-12-312021-12-31
Gross Profit Margin47.4%46.7%44.5%44.2%42.5%
Ebit Margin8.1%3.3%-1.7%-9.8%-2.9%
Ebitda Margin23.0%20.8%18.6%14.5%6.5%
Operating Profit Margin5.6%2.9%-2.7%-41.5%-10.3%
Pretax Profit Margin3.5%-3.9%-13.1%-42.7%-34.2%
Continuous Operations Profit Margin3.2%-4.3%-12.3%-40.2%-33.4%
Net Profit Margin3.1%-4.2%-12.1%-38.6%-33.3%
Bottom Line Profit Margin3.1%-4.2%-12.1%-38.6%-33.3%
Current Ratio2.8272.2572.0271.9672.052
Quick Ratio2.3451.7511.4851.3811.492
Solvency Ratio0.1000.1060.056-0.081-0.120
Cash Ratio1.3040.6650.4850.3010.380
Price To Earnings Ratio180.154-96.944-20.918-4.320-17.164
Price To Earnings Growth Ratio-1.0461.5320.308-0.029-0.634
Forward Price To Earnings Growth Ratio-1.0461.5320.308-0.029-0.634
Price To Earnings Diluted Ratio212.909-96.944-20.918-4.320-17.164
Price To Earnings Diluted Growth Ratio-1.3221.5320.308-0.029-0.634
Price To Book Ratio2.8862.3761.3560.8561.287
Price To Sales Ratio5.8204.1562.5131.6683.260
Price To Free Cash Flow Ratio50.38071.11534.643230.268-130.457
Price To Operating Cash Flow Ratio37.58336.09621.14330.3912,420.709
Debt To Assets Ratio0.3440.2730.2650.3100.276
Debt To Equity Ratio0.6610.4780.4860.6080.508
Debt To Capital Ratio0.3980.3230.3270.3780.337
Long Term Debt To Capital Ratio0.3910.3130.3160.3640.323
Financial Leverage Ratio1.9221.7511.8311.9591.841
Working Capital Turnover Ratio2.0372.8503.1463.0633.047
Operating Cash Flow Ratio0.4530.3760.3580.1610.004
Operating Cash Flow Sales Ratio0.1550.1150.1190.0550.001
Free Cash Flow Operating Cash Flow Ratio0.7460.5080.6100.132-18.556
Debt Service Coverage Ratio4.7952.9832.4662.5630.769
Interest Coverage Ratio1.2200.428-0.354-7.007-1.164
Short Term Operating Cash Flow Coverage Ratio89.56282.58379.3337.4340.231
Operating Cash Flow Coverage Ratio0.1160.1380.1320.0460.001
Capital Expenditure Coverage Ratio3.9372.0312.5661.1520.051
Dividend Paid And Capex Coverage Ratio3.9372.0312.5661.1520.051
Dividend Payout Ratio0.0000.0000.0000.0000.000
Enterprise Value Multiple29.15523.02717.48318.92168.250

Sparkline shows each ratio oldest → newest (left → right).

How the latest year compares

For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower

MetricCurrentvs 1Y agovs 5Y avg
Gross Profit Margin 47.4% ▲0.7% ▲2.3%
Ebit Margin 8.1% ▲4.8% ▲8.7%
Ebitda Margin 23.0% ▲2.2% ▲6.3%
Operating Profit Margin 5.6% ▲2.7% ▲14.8%
Pretax Profit Margin 3.5% ▲7.5% ▲21.6%
Continuous Operations Profit Margin 3.2% ▲7.5% ▲20.6%
Net Profit Margin 3.1% ▲7.3% ▲20.1%
Bottom Line Profit Margin 3.1% ▲7.3% ▲20.1%
Current Ratio 2.827 ▲0.570 ▲0.601
Quick Ratio 2.345 ▲0.593 ▲0.654
Solvency Ratio 0.100 ▼-0.006 ▲0.087
Cash Ratio 1.304 ▲0.639 ▲0.677
Price To Earnings Ratio 180.154 ▲277.098 ▲171.993
Price To Earnings Growth Ratio -1.046 ▼-2.578 ▼-1.072
Forward Price To Earnings Growth Ratio -1.046 ▼-2.578 ▼-1.072
Price To Earnings Diluted Ratio 212.909 ▲309.853 ▲198.197
Price To Earnings Diluted Growth Ratio -1.321 ▼-2.854 ▼-1.293
Price To Book Ratio 2.886 ▲0.510 ▲1.133
Price To Sales Ratio 5.820 ▲1.664 ▲2.337
Price To Free Cash Flow Ratio 50.380 ▼-20.735 ▼-0.810
Price To Operating Cash Flow Ratio 37.583 ▲1.487 ▼-471.601
Debt To Assets Ratio 0.344 ▲0.071 ▲0.050
Debt To Equity Ratio 0.661 ▲0.183 ▲0.113
Debt To Capital Ratio 0.398 ▲0.074 ▲0.045
Long Term Debt To Capital Ratio 0.391 ▲0.078 ▲0.050
Financial Leverage Ratio 1.923 ▲0.172 ▲0.061
Working Capital Turnover Ratio 2.037 ▼-0.813 ▼-0.792
Operating Cash Flow Ratio 0.453 ▲0.077 ▲0.183
Operating Cash Flow Sales Ratio 0.155 ▲0.040 ▲0.066
Free Cash Flow Operating Cash Flow Ratio 0.746 ▲0.238 ▲4.058
Debt Service Coverage Ratio 4.795 ▲1.811 ▲2.079
Interest Coverage Ratio 1.220 ▲0.792 ▲2.596
Short Term Operating Cash Flow Coverage Ratio 89.562 ▲6.979 ▲37.734
Operating Cash Flow Coverage Ratio 0.116 ▼-0.021 ▲0.029
Capital Expenditure Coverage Ratio 3.937 ▲1.906 ▲1.990
Dividend Paid And Capex Coverage Ratio 3.937 ▲1.906 ▲1.990
Dividend Payout Ratio 0.000 0.000 0.000
Enterprise Value Multiple 29.155 ▲6.128 ▼-2.212

Key metrics

MetricTrend20252024202320222021
Market cap$5.39B$3.58B$2.01B$1.20B$2.18B
Enterprise value$6.21B$4.12B$2.60B$1.97B$2.96B
EV / Sales6.71x4.79x3.25x2.75x4.42x
EV / Op. cash flow43.31x41.59x27.36x50.09x3283.60x
EV / Free cash flow58.06x81.94x44.84x379.52x-176.96x
EV / EBITDA29.16x23.03x17.48x18.92x68.25x
Net debt / EBITDA3.86x3.04x3.97x7.44x17.93x
Current ratio2.83x2.26x2.03x1.97x2.05x
Income quality4.98x-2.71x-0.98x-0.14x-0.01x
Graham number$5————
Graham net-net-$4-$3-$4-$5-$5
Tax burden88.1%106.5%92.0%90.3%97.4%
Interest burden43.7%-118.5%763.0%436.8%1165.8%
Working capital$577.6M$331.2M$272.9M$236.3M$232.4M
Invested capital$3.24B$2.35B$2.43B$2.47B$2.87B
Return on assets0.8%-1.4%-3.6%-10.1%-7.1%
Operating ROA1.7%0.9%-0.8%-10.2%-3.2%
Return on tangible assets2.6%-4.5%-13.2%-41.3%-34.3%
Return on equity1.5%-2.4%-6.5%-19.8%-13.1%
Return on invested capital1.4%1.0%-0.8%-11.3%-2.3%
Return on capital employed1.6%1.0%-0.9%-11.9%-2.4%
Earnings yield0.5%-1.0%-4.8%-23.1%-10.2%
Free cash flow yield2.0%1.4%2.9%0.4%-0.8%
Capex / Op. cash flow25.4%49.2%39.0%86.8%1955.6%
Capex / Depreciation26.4%32.4%22.8%19.6%28.0%
Capex / Sales3.9%5.7%4.6%4.8%2.6%
SG&A / Sales37.6%39.3%42.3%49.7%40.0%
R&D / Sales4.2%4.1%4.0%4.2%5.4%
Stock comp / Sales1.6%1.8%2.7%4.4%0.0%
Intangibles / Total assets69.1%69.7%73.1%75.5%79.2%
Days sales outstanding114d107d105d115d120d
Days payables outstanding43d45d48d62d56d
Operating cycle229d213d223d245d237d
Cash conversion cycle186d168d175d184d181d

Change by theme

Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.

Change over 1 year

Valuation
Market cap ▲+50.6%EV / Sales ▲+40.1%EV / EBITDA ▲+26.6%EV / Op. cash flow ▲+1.723Earnings yield ▲+0.015
Profitability
Return on equity ▲+0.039Return on assets ▲+0.022Return on invested capital ▲+0.004Return on capital employed ▲+0.005Operating ROA ▲+0.007Income quality ▲+7.683Tax burden ▼-0.184
Efficiency
Days sales outstanding ▲+6.978Days payables outstanding ▼-1.891Operating cycle ▲+15.475Cash conversion cycle ▲+17.366Capex / Sales ▼-0.017R&D / Sales ▲+0.001
Balance-sheet strength
Current ratio ▲+0.570Net debt / EBITDA ▲+0.815Working capital ▲+246400000.000Invested capital ▲+897700000.000Intangibles / Total assets ▼-0.006

Change over 5 years

Valuation
Market cap ▲+147.2%EV / Sales ▲+51.7%EV / EBITDA ▼-57.3%EV / Op. cash flow ▼-3240.282Earnings yield ▲+0.107
Profitability
Return on equity ▲+0.147Return on assets ▲+0.079Return on invested capital ▲+0.037Return on capital employed ▲+0.039Operating ROA ▲+0.048Income quality ▲+4.983Tax burden ▼-0.093
Efficiency
Days sales outstanding ▼-5.609Days payables outstanding ▼-13.408Operating cycle ▼-8.644Cash conversion cycle ▲+4.764Capex / Sales ▲+0.013R&D / Sales ▼-0.012
Balance-sheet strength
Current ratio ▲+0.776Net debt / EBITDA ▼-14.077Working capital ▲+345200000.000Invested capital ▲+371700000.000Intangibles / Total assets ▼-0.101

Employee count

Peer market caps